β-内酰胺类药物过敏评估与管理实用指南：加拿大过敏与临床免疫学会立场声明
Practical guide for evaluation and management of beta-lactam allergy: position statement from the Canadian Society of Allergy and Clinical Immunology.
作者信息
Jeimy Samira, Ben-Shoshan Moshe, Abrams Elissa M, Ellis Anne K, Connors Lori, Wong Tiffany
机构信息
Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, ON, N6A4V2, Canada.
Division of Allergy, Immunology and Dermatology, Department of Pediatrics, Montreal Children's Hospital, McGill University, Montreal, QC, Canada.
出版信息
Allergy Asthma Clin Immunol. 2020 Nov 10;16(1):95. doi: 10.1186/s13223-020-00494-2.
The vast majority of individuals labelled as allergic are not deemed truly allergic upon appropriate assessment by an allergist. A label of beta-lactam allergy carries important risks for individual and public health. This article provides an overview of beta-lactam allergy, implications of erroneous beta-lactam allergy labels and the impact that can be provided by structured allergy assessment. We provide recommendations on how to stratify risk of beta-lactam allergy, beta lactam challenge protocols as well as management of patients at high risk of beta-lactam allergy.
绝大多数被标记为过敏的个体，经过敏症专科医生进行适当评估后，并不被认为是真正过敏。β-内酰胺类过敏的标签对个人和公共健康都有重大风险。本文概述了β-内酰胺类过敏、错误的β-内酰胺类过敏标签的影响以及结构化过敏评估所能带来的作用。我们就如何对β-内酰胺类过敏风险进行分层、β-内酰胺类激发试验方案以及β-内酰胺类过敏高风险患者的管理提供了建议。
Zotero 插件